1. トップ >
  2. Medical Affairs Website >
  3. 精神領域Publication一覧

精神領域Publication一覧

　毎月更新予定
（最終更新：2024/10）

こちらには弊社社員が著者に含まれる論文や、弊社から資金提供・原薬提供などを行った研究論文を掲載しています。

精神領域

2024開く

    ＜英文＞

  • The specific anti-hostility effect of lurasidone in patients with an acute exacerbation of schizophrenia: results of pooled post hoc analyses in adolescents and adults.

    Citrome L et al. International Clinical Psychopharmacology 2024 Jul 22. doi: 10.1097/YIC.0000000000000563. Online ahead of print.

  • Effect of Lurasidone on Life Engagement in Schizophrenia: Post-Hoc Analysis of the JEWEL Study.

    H.Maruyama et al. Neuropsychiatric Disease and Treatment 2024:20 1453–1463

  • Long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies.

    Calisti F et al. Ann Gen Psychiatry. 2024 Jul 18;23(1):26.

  • Efficacy and safety of adding lurasidone to ongoing therapy with lithium or valproate for the treatment of an acute bipolar depressive episode.

    Tocco M et al. J Clin Psychopharmacol. 2024 Jul-Aug;44(4):345-352. doi: 10.1097/JCP.0000000000001850. Epub 2024 Apr 19.

  • Valuable interaction with cognitive remediation and optimal antipsychotics for recovery in schizophrenia (VICTORY-S): study protocol for an interventional, open-label, randomized comparison of combined treatment with cognitive remediation and lurasidone or paliperidone

    Kubota R et al. Front. Psychiatry. 2024 14:1331356.

  • Effect of Lurasidone on Social Functioning in Schizophrenia: Post Hoc Analysis of the JEWEL Study

    Miura I et al. J Clin Psychiatry. 2024 Jan 31;85(1):23m14881.

  • Factors associated with death, hospitalization, resignation, and sick leave from work among patients with schizophrenia in Japan: a nested case–control study using a large claims database

    Inada K et al. BMC Psychiatry. 2024 24:22.

  • Transcriptomic analyses of rats exposed to chronic mild stress:Modulation by chronic treatment with the antipsychotic drug lurasidone.

    Begni V. et al. Prog Neuropsychopharmacol Biol Psychiatry. 2024 Feb 8:129:110885.

    • ＜和文＞

  • 統合失調症患者の認知機能に対する精神科医アンケート調査

    篠原温美 , 遠矢俊司 ，髙井健太郎 , 増田孝裕, 中川伸 (山口大学大学院医学系研究科)｜最新精神医学 29巻 4号，263-272，2024

  • 日本人統合失調症患者を対象としたblonanserin テ-プ製剤長期投与におけるresolution/remission の出現の推移と治療継続率 2 つの長期臨床試験のpost hoc 解析

    井上 善文, 石郷岡 純, 中村 洋, ほか　臨床精神薬理 Volume 27, Issue 8, 859 - 875 , 2024

2023開く

    ＜英文＞

  • Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance

    Wei YM et al. World J Psychiatry. 2023 Nov 19;13(11):937-948.

  • Reduced sociability in a prenatal immune activation model: Modulation by a chronic blonanserin treatment through the amygdala-hippocampal axis.

    Deriha K. et al. J　Psychiatric Resarch. 2023;164(6):209-220

  • Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression.

    Singh M. et al. Curr Neuropharmacol. 2023;21(6):1393-1404.

  • The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar Depression: A Post Hoc Analysis

    Goldberg J. et al. J Clin Psychiatry 2023;84(4):22m14732

  • The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials.　

    M. Kato et al. J Affect Disord. 2023 Sep 15;337:150-158.

  • In Vitro Assessment of Compounded Lurasidone Suspensions for Enternal Feeding Tube.

    J. Wojcinski et al. Hosp Pharm. 2023 Jun;58(3):304-308.

  • A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression.

    T.Kishi et al. Neuropsychopharmacol Rep. 2023 Mar;43(1):137-140.

2022開く

    ＜英文＞

  • Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study.

    I.Miura et al. Neuropsychiatr Dis Treat. 2022 Nov 9;18:2627-2637.

  • Exposure to chronic stress impairs the ability to cope with an acute challenge: Modulation by lurasidone treatment.

    V.Begni et al. Eur Neuropsychopharmacol. 2022 Aug;61:78-90.

  • Early improvement as a predictor of later response to lurasidone in schizophrenia from Japan trials: A diagnostic test.

    T.Kishi et al. Psychiatry Clin Neurosci. 2022 Aug;76(8):401-402.

  • Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial.

    Chengcheng Pu et al. BMJ Open. 2022 Apr 20;12(4):e054079.

  • Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression.

    Melissa P. DelBello et al. J Am Acad Child Adolesc Psychiatry. 2022 Feb;61(2):243-254.

  • Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study.

    K.Ohi et al. Prog Neuropsychopharmacol Biol Psychiatry. 2022 Mar 8;113:110470.

  • Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.

    T.Saito et al. J Child Adolesc Psychopharmacol. 2022 Feb;32(1):12-23.

  • Early improvement as a predictor of response to blonanserin transdermal patch in patients with schizophrenia.

    T.Kishi et al. Schizophr Res. 2022 Feb;240:231-232.

  • Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study.

    T.Saito et al. J Child Adolesc Psychopharmacol. 2022 Feb;32(1):24-35.

  • Burden of schizophrenia among Japanese patients: a cross-sectional National Health and Wellness Survey.

    K.Baba et al. BMC Psychiatry. 2022 Jun 18;22(1):410.

    • ＜和文＞

  • 【二次出版】統合失調症患者におけるlurasidoneの安全性及び有効性　12週間非盲検継続投与試験

    伊豫雅臣ら　臨床精神薬理, 2022, 25巻5号 P.573-590.

  • 【二次出版】青年期統合失調症患者を対象としたblonanserin経口剤の長期投与による安全性と有効性の検討　検証試験から継続した52週間多施設共同非盲検長期投与試験

    齊藤卓弥ら　臨床精神薬理, 2022, 25巻6号 P.719-736.

  • 【二次出版】青年期統合失調症患者を対象としたblonanserin経口剤の有効性と安全性の検討　6週間ランダム化プラセボ対照試験

    齊藤卓弥ら　臨床精神薬理, 2022, 25巻6号 P.701-718.

  • 統合失調症患者を対象としたblonanserin経皮吸収型テープ製剤の適用部位皮膚関連有害事象の検討　一般使用成績調査の結果と追加解析

    中村洋ら　臨床精神薬理, 2022, 25巻4号 P.435-454.

  • 【二次出版】日本人の双極I型障害患者を対象としたlurasidoneの長期投与試験　52週間非盲検試験

    樋口輝彦ら　臨床精神薬理, 2022, 25巻3号 P.333-349

  • 【二次出版】急性増悪期の統合失調症患者におけるlurasidoneの有効性および安全性　6週間、ランダム化、二重盲検、プラセボ対照試験

    伊豫雅臣ら　臨床精神薬理, 2022, 25巻2号 P.205-220

2021開く

    ＜英文＞

  • Differences in the incidence of lurasidone adverse events between depressive disorders and schizophrenia in double-blind, randomized, placebo-controlled trials: a meta-analysis.

    T.Kishi et al. Psychopharmacology (Berl). 2021 Dec;238(12):3585-3593.

  • Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study.

    M.Iyo et al. Neuropsychiatr Dis Treat. 2021 Aug 16;17:2683-2695.

  • Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study.

    T.Higuchi et al. Int J Bipolar Disord. 2021 Aug 2;9(1):25.

  • Stress Modifies the Expression of Glucocorticoid-Responsive Genes by Acting at Epigenetic Levels in the Rat Prefrontal Cortex: Modulatory Activity of Lurasidone.

    P.Brivio et al. Int J Mol Sci. 2021 Jun 8;22(12):6197.

  • Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis.

    A.Kadakia et al. BMC Psychiatry. 2021 May 11;21(1):249.

  • Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study.

    M.Iyo et al. Psychiatry Clin Neurosci. 2021 Apr 23;75(7):227-35.

  • Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients.

    T.Sakayori et al. Psychopharmacology (Berl). 2021 May;238(5):1343-1350.

  • Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies.

    M.Murasaki et al. Ann Gen Psychiatry. 2021 Sep 7;20(1):41.

  • Impact of bipolar disorder on health-related quality of life and work productivity: Estimates from the national health and wellness survey in Japan.

    T.Kato et al. J Affect Disord. 2021 Dec 1;295:203-214.

  • Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.

    T.Kishimoto et al. Lancet Psychiatry. 2021 May;8(5):387-404.

  • Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia: A Systematic Review and Meta-analysis.

    K.Hagi et al. JAMA Pshychiatry. 2021 May 1 ; 78(5): 510-518

  • Antidepressive Effect of Antipsychotics in the Treatment of Schizophrenia: Meta-Regression Analysis of Randomized Placebo-Controlled Trials.

    I.Miura et al. Int J Neuropsychopharmacol. 2021 Mar 17;24(3):200-215.

  • Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study.

    J.Ishigooka et al. J Affect Disord. 2021 Feb 15;281:160-167.

  • Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.

    Y.Inoue et al. J Pharmacol Sci. 2021 Jan;145(1):42-51.

    • ＜和文＞

  • Lurasidoneの双極I型障害の抑うつエピソードの患者を対象とした第III相試験(ELEVATE試験)の部分集団解析　日本の実施医療機関で集積された被験者データの傾向

    加藤忠史ら　臨床精神薬理, 2021, 24巻12号 P.1265-1275

  • 【二次出版】Lurasidoneの抑うつエピソードを伴う双極I型障害患者に対する長期投与試験:28週間非盲検継続投与試験

    石郷岡純ら　臨床精神薬理, 2021, 24巻10号 P.1049-1071

  • 【二次出版】抑うつエピソードを伴う双極I型障害患者に対するlurasidone単剤治療　ランダム化プラセボ対照二重盲検比較試験

    加藤忠史ら　臨床精神薬理, 2021, 24巻4号 P.387-405

2020開く

    ＜英文＞

  • Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression.

    T.Kato et al. Psychiatry Clin Neurosci. 2020 Dec;74(12):635-644.

  • Long-term effects of stress early in life on microRNA-30a and its network: Preventive effects of lurasidone and potential implications for depression vulnerability.

    A.Cattaneo et al. Neurobiol Stress. 2020 Nov 23;13:100271.

  • Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan.

    T.Kishi et al. Neuropsychopharmacol Rep. 2020 Sep;40(3):314-322.

  • Effect of lurasidone treatment on chronic mild stress-induced behavioural deficits in male rats: The potential role for glucocorticoid receptor signalling.

    F.Calabrese et al. J Psychopharmacol. 2020 Apr;34(4):420-428.

  • A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.

    T.Niitsu et al. Asian J Psychiatr. 2020 Oct;53:102369.

  • Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database.

    Y.Takekita et al. Neuropsychiatr Dis Treat. 2020 Nov 30;16:2871-2879.

  • A propensity score matching analysis for cardio metabolic risk of antipsychotics in patients with schizophrenia using Japanese claims data.

    I.Kusumi et al. BMC Psychiatry. 2020 Dec 9;20(1):584.

  • Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study.

    T.Higuchi et al. Asia Pac Psychiatry. 2020 Mar;12(1):e12377.

  • Chronic treatment with the antipsychotic drug blonanserin modulates the responsiveness to acute stress with anatomical selectivity.

    F. Marchisella et al. Psychopharmacology (Berl). 2020 Jun;237(6):1783-1793.

  • Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.

    N.Iwata et al. CNS Drugs. 2020 Jan;34(1):103-116.

  • Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.

    Philip D Harvey et al. Neuropsychopharmacol Rep. 2020 Mar;40(1):63-72.

  • Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.

    N.Iwata et al. Schizophr Res. 2020 Jan;215:408-415.

    • ＜和文＞

  • 【二次出版】日本人統合失調症患者を対象とした経皮吸収型blonanserinテープ製剤の長期間貼付による安全性と有効性　52週間非盲検多施設共同試験

    岩田仲生ら 臨床精神薬理, 2020, 23巻3号 P.313-336

  • 【二次出版】統合失調症患者を対象とした経皮吸収型blonanserinテープ製剤の有効性と安全性の検討　無作為化割付け6週間二重盲検プラセボ対照多施設共同試験

    岩田仲生ら 臨床精神薬理, 2020, 23巻3号 P.295-312

  • 統合失調症患者を対象とした経皮吸収型blonanserinテープ製剤の有効性と安全性の検討:多施設共同、無作為化、二重盲検プラセボ対照試験に続く非盲検継続試験

    岩田仲生ら 臨床精神薬理, 2020, 23巻3号 P.283-294

2019開く

    ＜英文＞

  • Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia

    Afzal J et al. Neurol Ther. 2019 8:215-230.

  • Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients.

    T.Higuchi et al. Asia Pac Psychiatry. 2019 Jun;11(2):e12352.

  • Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial.

    T.Higuchi et al. Asia Pac Psychiatry. 2019 Sep;11(3):e12354.

  • Blonanserin ameliorates social deficit through dopamine-D3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia.

    S.Takeuchi et al. Neurochem Int. 2019 Sep;128:127-134.

  • Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.

    Philip D.Harvey et al. Neuropsychopharmacol Rep. 2019 Sep;39(3):173-182.

  • Antidepressant activities of escitalopram and blonanserin on prenatal and adolescent combined stress-induced depression model: Possible role of neurotrophic mechanism change in serum and nucleus accumbens.

    K.Furuse et al. J Affect Disord. 2019 Mar 15;247:97-104.

  • Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.

    T.Masuda et al. JAMA Psychiatry. 2019 Oct 1;76(10):1052-1062.

  • Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials.

    T.Kishi et al. Pharmacopsychiatry. 2019 Feb;52(2):52-62.

  • Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.

    T.Kishimoto et al. World Psychiatry. 2019 Jun;18(2):208-224.

    • ＜和文＞

  • 急性増悪期統合失調症患者におけるblonanserin治療反応の早期予測　特定使用成績調査の結果より

    土森紀美子ら　臨床精神薬理, 2019, 22巻12号 P.1223-1235

2018開く

    ＜英文＞

  • Chronic Stress Exposure Reduces Parvalbumin Expression in the Rat Hippocampus through an Imbalance of Redox Mechanisms: Restorative Effect of the Antipsychotic Lurasidone.

    Andrea C.Rossetti et al. Int J Neuropsychopharmacol. 2018 Sep 1;21(9):883-893.

  • Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction.

    L.Ragagopal et al. Behav Brain Res. 2018 Sep 17;350:31-43.

  • Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol.

    T.Hashimoto et al. Eur J Pharmacol. 2018 Jul 5;830:26-32.

  • Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies.

    T.Kishimoto et al. Schizophr Bull. 2018 Apr 6;44(3):603-619.

    • ＜和文＞

  • ドパミンD3受容体遮断による統合失調症の新たな治療の可能性

    井上善文　臨床精神医学, 2018, 47巻3号　P.307-313

2017開く

    ＜英文＞

  • Lurasidone in post-menopausal females with major depressive disorder with mixed features: Post-hoc analysis of a placebo-controlled trial.

    Sramek J et al. Progress in Neuropsychopharmacology & Biological Psychiatry. 2017;78 12-17.

  • Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.

    B.Galling et al. World Psychiatry. 2017 Feb;16(1):77-89.

  • Neurochemical arguments for the use of dopamine D4 receptor stimulation to improve cognitive impairment associated with schizophrenia.

    M.Huang et al. Pharmacol Biochem Behav. 2017 Jun;157:16-23.

  • Antipsychotics promote GABAergic interneuron genesis in the adult rat brain: Role of heat-shock protein production.

    H.Kaneta et al. J Psychiatr Res. 2017 Sep;92:108-118.

  • Effects of clozapine on adipokine secretions/productions and lipid droplets in 3T3-L1 adipocytes.

    T.Tsubai et al. J Pharmacol Sci. 2017 Feb;133(2):79-87.

  • Chronic lurasidone treatment normalizes GABAergic marker alterations in the dorsal hippocampus of mice exposed to prenatal immune activation.

    A.Luoni et al. Eur Neuropsychopharmacol. 2017 Feb;27(2):170-179.

    • ＜和文＞

  • 急性増悪期統合失調症患者を対象としたblonanserin特定使用成績調査　日常診療下でのblonanserin投与状況と12週投与の安全性・有効性の検討

    土森紀美子ら　臨床精神薬理, 2017, 20巻11号 P.1311-1334

2016開く

    ＜英文＞

  • Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis.

    Jian-Ping Zhang et al. Schizophr Bull. 2016 Nov;42(6):1418-1437.

  • Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.

    F.Misawa et al. Schizophr Res. 2016 Oct;176(2-3):220-230.

  • Variants in the DRD2 locus and antipsychotic-related prolactin levels:A meta-analysis.

    I.Miura et al. Psychoneuroendocrinology. 2016 Oct;72:1-10.

  • Safety and tolerability of antipsychotic cotreatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.

    B.Galling et al. Expert Opin Drug Saf. 2016 May;15(5):591-612.

  • Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasidone treatment.

    F.Calabrese et al. Pharmacol Res. 2016 Feb;104:140-50.

    • ＜和文＞

  • 糖尿病合併統合失調症患者を対象としたblonanserin特定使用成績調査　日常診療下でのblonanserin 12ヵ月投与の安全性・有効性の検討

    土森紀美子ら　臨床精神薬理, 2016, 19巻12号 P.1745-1766

  • 統合失調症患者を対象としたblonanserin使用成績調査症例の1年間の追跡調査　日常診療下でのblonanserin長期投与の安全性・有効性の検討

    長尾宗彦ら　臨床精神薬理, 2016, 19巻5号 P.617-631

  • 抗精神病薬未治療の初発統合失調症患者を対象としたblonanserin特定使用成績調査　日常診療下でのblonanserin 12週投与の安全性・有効性の検討

    川口奈美ら　臨床精神薬理, 2016, 19巻4号 P.471-482

2015開く

    ＜英文＞

  • Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis.

    B.Galling et al. Expert Opin Drug Saf. 2015 Aug;14(8):1181-99.

  • Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study.

    Philip D.Harvey et al. Schizophr Res. 2015 Aug;166(1-3):334-8.

  • Blonanserin Ameliorates Phencyclidine-Induced Visual-Recognition Memory Deficits: the Complex Mechanism of Blonanserin Action Involving D3-5-HT2A and D1-NMDA Receptors in the mPFC.

    H.Hida et al. Neuropsychopharmacology. 2015 Feb;40(3):601-13.

  • Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin.

    A.tatara et al. Pharmacol Biochem Behav. 2015 Nov;138:14-9.

    • ＜和文＞

  • 統合失調症患者に対する日常診療下でのblonanserin 12週投与の安全性・有効性の検討　使用成績調査より

    増田孝裕ら　臨床精神薬理, 2015, 18巻6号 P.769-784

2014開く

    ＜英文＞

  • Lurasidone Exerts Antidepressant Properties in the Chronic Mild Stress Model through the Regulation of Synaptic and Neuroplastic Mechanisms in the Rat Prefrontal Cortex.

    A.Luoni et al. Int J Neuropsychopharmacol. 2014 Oct 31;18(4):pyu061.

  • Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence.

    A.Luoni et al. Eur Neuropsychopharmacol. 2014 Jun;24(6):986-95.

  • Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment.

    A.Luoni et al. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 3;50:94-101.

  • Comprehensive DNA methylation analysis of human neuroblastoma cells treated with blonanserin.

    Y.Murata et al. Neurosci Lett. 2014 Mar 20;563:123-8.

  • Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

    T.Kishi et al. PLoS One. 2014 Feb 4;9(2):e88049.

2013開く

    ＜英文＞

  • Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats.

    A.Luoni et al. Int J Neuropsychopharmacol. 2013 Jul;16(6):1319-30.